{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:20:16Z","timestamp":1788542416676,"version":"build-2803163510"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s00044-024-03267-3","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T18:03:48Z","timestamp":1719425028000},"page":"1339-1353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Targeting cAMP signaling and phosphodiesterase 4 for liver disease treatment"],"prefix":"10.1007","volume":"33","author":[{"given":"Jingyi","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalton W.","family":"Staler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3588-0434","authenticated-orcid":false,"given":"Ram I.","family":"Mahato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"3267_CR1","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Wong G, Anstee QM, Henry L. The global burden of liver disease. Clin Gastroenterol Hepatol. 2023;21:1978\u201391.","DOI":"10.1016\/j.cgh.2023.04.015"},{"key":"3267_CR2","doi-asserted-by":"crossref","unstructured":"Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516\u201337.","DOI":"10.1016\/j.jhep.2023.03.017"},{"key":"3267_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, Sanyal A, Neuschwander-Tetri B, Tiribelli C, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999\u20132014.e1.","journal-title":"Gastroenterology"},{"key":"3267_CR4","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","volume":"29","author":"ML Teng","year":"2023","unstructured":"Teng ML, Ng CH, Huang DQ, Chan KE, Tan DJ, Lim WH, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29:S32.","journal-title":"Clin Mol Hepatol"},{"key":"3267_CR5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/hep.30866","volume":"71","author":"DW Crabb","year":"2020","unstructured":"Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR. Diagnosis and treatment of alcohol\u2010associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2020;71:306\u201333.","journal-title":"Hepatology"},{"key":"3267_CR6","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","volume":"77","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797\u2013835.","journal-title":"Hepatology"},{"key":"3267_CR7","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/j.1600-6143.2011.03587.x","volume":"11","author":"JA Wertheim","year":"2011","unstructured":"Wertheim JA, Petrowsky H, Saab S, Kupiec-Weglinski JW, Busuttil RW. Major challenges limiting liver transplantation in the United States. Am J Transplant. 2011;11:1773\u201384.","journal-title":"Am J Transplant"},{"key":"3267_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s12072-009-9148-8","volume":"3","author":"AC Chan","year":"2009","unstructured":"Chan AC, Fan ST, Lo CM, Liu CL, Chan SC, Ng KK, et al. Liver transplantation for acute-on-chronic liver failure. Hepatol Int. 2009;3:571\u201381.","journal-title":"Hepatol Int"},{"key":"3267_CR9","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1146\/annurev.nutr.18.1.353","volume":"18","author":"PB Daniel","year":"1998","unstructured":"Daniel PB, Walker WH, Habener JF. Cyclic AMP signaling and gene regulation. Annu Rev Nutr. 1998;18:353\u201383.","journal-title":"Annu Rev Nutr"},{"key":"3267_CR10","doi-asserted-by":"publisher","first-page":"10594","DOI":"10.1021\/acs.jmedchem.9b02170","volume":"63","author":"T Peng","year":"2020","unstructured":"Peng T, Qi B, He J, Ke H, Shi J. Advances in the development of phosphodiesterase-4 inhibitors. J Med Chem. 2020;63:10594\u2013617.","journal-title":"J Med Chem"},{"key":"3267_CR11","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S0021-9258(19)77423-7","volume":"232","author":"EW Sutherland","year":"1958","unstructured":"Sutherland EW, Rall TW. Fractionation and characterization of a cyclic adenine ribonucleotide formed by tissue particles. J Biol Chem. 1958;232:1077\u201391.","journal-title":"J Biol Chem"},{"key":"3267_CR12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1124\/pharmrev.120.000086","volume":"73","author":"M Zaccolo","year":"2021","unstructured":"Zaccolo M, Zerio A, Lobo MJ. Subcellular organization of the cAMP signaling pathway. Pharmacol Rev. 2021;73:278\u2013309.","journal-title":"Pharmacol Rev"},{"key":"3267_CR13","unstructured":"Rehman S, Rahimi N, Dimri M. Biochemistry, G Protein Coupled Receptors. 2023 Jul 30. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024."},{"key":"3267_CR14","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1021\/acs.jmedchem.2c01309","volume":"66","author":"Y Shi","year":"2023","unstructured":"Shi Y, Chen Y, Deng L, Du K, Lu S, Chen T. Structural understanding of peptide-bound G protein-coupled receptors: peptide\u2013target interactions. J Med Chem. 2023;66:1083\u2013111.","journal-title":"J Med Chem"},{"key":"3267_CR15","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1152\/physrev.00021.2020","volume":"101","author":"D Calebiro","year":"2021","unstructured":"Calebiro D, Koszegi Z, Lanoisel\u00e9e Y, Miljus T, O\u2019Brien S. G protein-coupled receptor-G protein interactions: a single-molecule perspective. Physiol Rev. 2021;101:857\u2013906.","journal-title":"Physiol Rev"},{"key":"3267_CR16","doi-asserted-by":"publisher","first-page":"941870","DOI":"10.3389\/fcell.2022.941870","volume":"10","author":"S Villaseca","year":"2022","unstructured":"Villaseca S, Romero G, Ruiz MJ, P\u00e9rez C, Leal JI, Tovar LM, et al. G\u03b1i protein subunit: a step toward understanding its non-canonical mechanisms. Front Cell Dev Biol. 2022;10:941870.","journal-title":"Front Cell Dev Biol"},{"key":"3267_CR17","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.npep.2005.10.002","volume":"40","author":"GD Dalton","year":"2006","unstructured":"Dalton GD, Dewey WL. Protein kinase inhibitor peptide (PKI): a family of endogenous neuropeptides that modulate neuronal cAMP-dependent protein kinase function. Neuropeptides. 2006;40:23\u201334.","journal-title":"Neuropeptides"},{"key":"3267_CR18","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/35073073","volume":"2","author":"JL Bos","year":"2001","unstructured":"Bos JL, de Rooij J, Reedquist KA. Rap1 signalling: adhering to new models. Nat Rev Mol Cell Biol. 2001;2:369\u201377.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3267_CR19","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1152\/physrev.00025.2017","volume":"98","author":"WG Robichaux III","year":"2018","unstructured":"Robichaux WG III, Cheng X. Intracellular cAMP sensor EPAC: physiology, pathophysiology, and therapeutics development. Physiol Rev. 2018;98:919\u20131053.","journal-title":"Physiol Rev"},{"key":"3267_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-024-01524-x","volume":"17","author":"H Zhang","year":"2024","unstructured":"Zhang H, Liu Y, Liu J, Chen J, Wang J, Hua H, et al. cAMP-PKA\/EPAC signaling and cancer: the interplay in tumor microenvironment. J Hematol Oncol. 2024;17:5.","journal-title":"J Hematol Oncol"},{"key":"3267_CR21","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1210\/er.2013-1053","volume":"35","author":"MF Azevedo","year":"2014","unstructured":"Azevedo MF, Faucz FR, Bimpaki E, Horvath A, Levy I, de Alexandre RB, et al. Clinical and molecular genetics of the phosphodiesterases (PDEs). Endocr Rev. 2014;35:195\u2013233.","journal-title":"Endocr Rev"},{"key":"3267_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1042\/BJ20070970","volume":"408","author":"H Wang","year":"2007","unstructured":"Wang H, Peng M-S, Chen Y, Geng J, Robinson H, Houslay MD, et al. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem J. 2007;408:193\u2013201.","journal-title":"Biochem J"},{"key":"3267_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12862-016-0695-z","volume":"16","author":"D Lagman","year":"2016","unstructured":"Lagman D, Franz\u00e9n IE, Eggert J, Larhammar D, Abalo XM. Evolution and expression of the phosphodiesterase 6 genes unveils vertebrate novelty to control photosensitivity. BMC Evolut Biol. 2016;16:1\u201320.","journal-title":"BMC Evolut Biol"},{"key":"3267_CR24","unstructured":"Padda IS, Tripp J. Phosphodiesterase Inhibitors. [Updated 2023 Jun 26]. In: StatPearls [Internet]. TreasureIsland (FL): StatPearls Publishing; 2024. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK559276\/."},{"key":"3267_CR25","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/obr.12385","volume":"17","author":"C Wu","year":"2016","unstructured":"Wu C, Rajagopalan S. Phosphodiesterase\u20104 inhibition as a therapeutic strategy for metabolic disorders. Obes Rev. 2016;17:429\u201341.","journal-title":"Obes Rev"},{"key":"3267_CR26","doi-asserted-by":"publisher","first-page":"5493","DOI":"10.1074\/jbc.R200029200","volume":"278","author":"M Conti","year":"2003","unstructured":"Conti M, Richter W, Mehats C, Livera G, Park J-Y, Jin C. Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem. 2003;278:5493\u20136.","journal-title":"J Biol Chem"},{"key":"3267_CR27","doi-asserted-by":"publisher","first-page":"5471","DOI":"10.1021\/jm800582j","volume":"51","author":"A Kodimuthali","year":"2008","unstructured":"Kodimuthali A, Jabaris SSL, Pal M. Recent advances on phosphodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. J Med Chem. 2008;51:5471\u201389.","journal-title":"J Med Chem"},{"key":"3267_CR28","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1590\/S0074-02762005000900023","volume":"100","author":"V Lagente","year":"2005","unstructured":"Lagente V, Martin-Chouly C, Boichot E, Martins MA, Silva PM. Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases. Mem Inst Oswaldo Cruz. 2005;100:131\u20136.","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"3267_CR29","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.rmed.2003.12.012","volume":"98","author":"AM Vignola","year":"2004","unstructured":"Vignola AM. PDE4 inhibitors in COPD\u2014a more selective approach to treatment. Respir Med. 2004;98:495\u2013503.","journal-title":"Respir Med"},{"key":"3267_CR30","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1517\/13543784.10.7.1361","volume":"10","author":"MA Giembycz","year":"2001","unstructured":"Giembycz MA. Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease. Expert Opin Investig Drugs. 2001;10:1361\u201379.","journal-title":"Expert Opin Investig Drugs"},{"key":"3267_CR31","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1006\/pupt.1999.0181","volume":"12","author":"T Torphy","year":"1999","unstructured":"Torphy T, Barnette M, Underwood D, Griswold D, Christensen S, Murdoch R, et al. ArifloTM (SB 207499), a second generation phosphodiesterase 4 inhibitor for the treatment of asthma and COPD: from concept to clinic. Pulm Pharmacol Ther. 1999;12:131\u20135.","journal-title":"Pulm Pharmacol Ther"},{"key":"3267_CR32","doi-asserted-by":"publisher","first-page":"220206","DOI":"10.1183\/16000617.0206-2022","volume":"32","author":"M Kolb","year":"2023","unstructured":"Kolb M. Phosphodiesterase 4B inhibition: a potential novel strategy for treating pulmonary fibrosis.\u201d M. Kolb, B. Crestani and TM Maher. Eur Respir Rev. 2023;32:220206. 2024","journal-title":"Eur Respir Rev"},{"key":"3267_CR33","doi-asserted-by":"publisher","first-page":"2178","DOI":"10.1056\/NEJMoa2201737","volume":"386","author":"L Richeldi","year":"2022","unstructured":"Richeldi L, Azuma A, Cottin V, Hesslinger C, Stowasser S, Valenzuela C, et al. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N. Engl J Med. 2022;386:2178\u201387.","journal-title":"N. Engl J Med"},{"key":"3267_CR34","doi-asserted-by":"publisher","first-page":"6794","DOI":"10.1016\/j.bmcl.2012.09.028","volume":"22","author":"MP DeNinno","year":"2012","unstructured":"DeNinno MP. Future directions in phosphodiesterase drug discovery. Bioorg Med Chem Lett. 2012;22:6794\u2013800.","journal-title":"Bioorg Med Chem Lett"},{"key":"3267_CR35","doi-asserted-by":"publisher","first-page":"519743","DOI":"10.3389\/fphar.2020.00259","volume":"11","author":"JE Phillips","year":"2020","unstructured":"Phillips JE. Inhaled phosphodiesterase 4 (PDE4) inhibitors for inflammatory respiratory diseases. Front Pharmacol. 2020;11:519743.","journal-title":"Front Pharmacol"},{"key":"3267_CR36","doi-asserted-by":"publisher","first-page":"e14261","DOI":"10.1111\/dth.14261","volume":"33","author":"D Nassim","year":"2020","unstructured":"Nassim D, Alajmi A, Jfri A, Pehr K. Apremilast in dermatology: a review of literature. Dermatol Ther. 2020;33:e14261.","journal-title":"Dermatol Ther"},{"key":"3267_CR37","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s13555-020-00389-5","volume":"10","author":"K Fahrbach","year":"2020","unstructured":"Fahrbach K, Tarpey J, Washington EB, Hughes R, Thom H, Neary MP, et al. Crisaborole ointment, 2%, for treatment of patients with mild-to-moderate atopic dermatitis: systematic literature review and network meta-analysis. Dermatol Ther. 2020;10:681\u201394.","journal-title":"Dermatol Ther"},{"key":"3267_CR38","doi-asserted-by":"publisher","first-page":"e000365","DOI":"10.1136\/openhrt-2015-000365","volume":"3","author":"MF McCarty","year":"2016","unstructured":"McCarty MF, O\u2019Keefe JH, DiNicolantonio JJ. Pentoxifylline for vascular health: a brief review of the literature. Open Heart. 2016;3:e000365.","journal-title":"Open Heart"},{"key":"3267_CR39","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/ph3030725","volume":"3","author":"PJ Barnes","year":"2010","unstructured":"Barnes PJ. Theophylline. Pharmaceuticals. 2010;3:725\u201347.","journal-title":"Pharmaceuticals"},{"key":"3267_CR40","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1111\/j.1365-2125.2008.03270.x","volume":"66","author":"P Rolan","year":"2008","unstructured":"Rolan P, Gibbons JA, He L, Chang E, Jones D, Gross MI, et al. Ibudilast in healthy volunteers: safety, tolerability and pharmacokinetics with single and multiple doses. Br J Clin Pharmacol. 2008;66:792\u2013801.","journal-title":"Br J Clin Pharmacol"},{"key":"3267_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nrgastro.2011.134","volume":"8","author":"J Altamirano","year":"2011","unstructured":"Altamirano J, Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nat Rev Gastroenterol Hepatol. 2011;8:491\u2013501.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3267_CR42","doi-asserted-by":"publisher","first-page":"840752","DOI":"10.3389\/fmed.2022.840752","volume":"9","author":"L Chen","year":"2022","unstructured":"Chen L, Zhu Y, Hou X, Yang L, Chu H. The role of gut bacteria and fungi in alcohol-associated liver disease. Front Med. 2022;9:840752.","journal-title":"Front Med"},{"key":"3267_CR43","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev-nutr-072610-145138","volume":"32","author":"HJ Wang","year":"2012","unstructured":"Wang HJ, Gao B, Zakhari S, Nagy LE. Inflammation in alcoholic liver disease. Annu Rev Nutr. 2012;32:343\u201368.","journal-title":"Annu Rev Nutr"},{"key":"3267_CR44","doi-asserted-by":"publisher","first-page":"G516","DOI":"10.1152\/ajpgi.00537.2010","volume":"300","author":"B Gao","year":"2011","unstructured":"Gao B, Seki E, Brenner DA, Friedman S, Cohen JI, Nagy L, et al. Innate immunity in alcoholic liver disease. Am J Physiol-Gastrointest Liver Physiol. 2011;300:G516\u2013G25.","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"3267_CR45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1751-2980.2011.00569.x","volume":"13","author":"H Zhu","year":"2012","unstructured":"Zhu H, Jia Z, Misra H, Li YR. Oxidative stress and redox signaling mechanisms of alcoholic liver disease: updated experimental and clinical evidence. J Dig Dis. 2012;13:133\u201342.","journal-title":"J Dig Dis"},{"key":"3267_CR46","doi-asserted-by":"publisher","first-page":"9686","DOI":"10.3390\/ijms22189686","volume":"22","author":"A Birkov\u00e1","year":"2021","unstructured":"Birkov\u00e1 A, Hubkov\u00e1 B, \u010ci\u017em\u00e1rov\u00e1 B, Boler\u00e1zska B. Current view on the mechanisms of alcohol-mediated toxicity. Int J Mol Sci. 2021;22:9686.","journal-title":"Int J Mol Sci"},{"key":"3267_CR47","doi-asserted-by":"publisher","first-page":"17756","DOI":"10.3748\/wjg.v20.i47.17756","volume":"20","author":"E Ceni","year":"2014","unstructured":"Ceni E, Mello T, Galli A. Pathogenesis of alcoholic liver disease: role of oxidative metabolism. World J Gastroenterol. 2014;20:17756.","journal-title":"World J Gastroenterol"},{"key":"3267_CR48","doi-asserted-by":"publisher","first-page":"S272","DOI":"10.1111\/j.1440-1746.1997.tb00510.x","volume":"12","author":"H Ishii","year":"1997","unstructured":"Ishii H, Kurose I, Kato S. Pathogenesis of alcoholic liver disease with particular emphasis on oxidative stress. J Gastroenterol Hepatol. 1997;12:S272\u2013S82.","journal-title":"J Gastroenterol Hepatol"},{"key":"3267_CR49","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nrgastro.2017.32","volume":"14","author":"NL Gluchowski","year":"2017","unstructured":"Gluchowski NL, Becuwe M, Walther TC, Farese RV. Lipid droplets and liver disease: from basic biology to clinical implications. Nat Rev Gastroenterol Hepatol. 2017;14:343\u201355.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3267_CR50","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2018.10.037","volume":"70","author":"M You","year":"2019","unstructured":"You M, Arteel GE. Effect of ethanol on lipid metabolism. J Hepatol. 2019;70:237\u201348.","journal-title":"J Hepatol"},{"key":"3267_CR51","doi-asserted-by":"publisher","first-page":"E10","DOI":"10.1152\/ajpendo.00011.2008","volume":"295","author":"M Sozio","year":"2008","unstructured":"Sozio M, Crabb DW. Alcohol and lipid metabolism. Am J Physiol-Endocrinol Metab. 2008;295:E10\u2013E6.","journal-title":"Am J Physiol-Endocrinol Metab"},{"key":"3267_CR52","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S0022-2275(20)40613-3","volume":"20","author":"E Baraona","year":"1979","unstructured":"Baraona E, Lieber CS. Effects of ethanol on lipid metabolism. J Lipid Res. 1979;20:289\u2013315.","journal-title":"J Lipid Res"},{"key":"3267_CR53","doi-asserted-by":"publisher","first-page":"G194","DOI":"10.1152\/ajpgi.00413.2005","volume":"290","author":"MW Bradbury","year":"2006","unstructured":"Bradbury MW. Lipid metabolism and liver inflammation. I. Hepatic fatty acid uptake: possible role in steatosis. Am J Physiol-Gastrointest Liver Physiol. 2006;290:G194\u2013G8.","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"3267_CR54","doi-asserted-by":"publisher","first-page":"S56","DOI":"10.1111\/j.1440-1746.2006.04582.x","volume":"21","author":"DW Crabb","year":"2006","unstructured":"Crabb DW, Liangpunsakul S. Alcohol and lipid metabolism. J Gastroenterol Hepatol. 2006;21:S56\u2013S60.","journal-title":"J Gastroenterol Hepatol"},{"key":"3267_CR55","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1194\/jlr.R119000547","volume":"61","author":"S Jeon","year":"2020","unstructured":"Jeon S, Carr R. Alcohol effects on hepatic lipid metabolism. J Lipid Res. 2020;61:470\u20139.","journal-title":"J Lipid Res"},{"key":"3267_CR56","doi-asserted-by":"publisher","first-page":"G852","DOI":"10.1152\/ajpgi.00521.2005","volume":"290","author":"JK Reddy","year":"2006","unstructured":"Reddy JK, Sambasiva Rao M. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol-Gastrointest Liver Physiol. 2006;290:G852\u2013G8.","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"3267_CR57","first-page":"433","volume":"5","author":"N Barlas","year":"1983","unstructured":"Barlas N, Mutchnick M, Grant G, Trainin N. The effect of thymic humoral factor on intracellular lymphocyte cyclic AMP in alcoholic liver disease. Thymus. 1983;5:433\u20137.","journal-title":"Thymus"},{"key":"3267_CR58","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1073\/pnas.84.5.1413","volume":"84","author":"I Diamond","year":"1987","unstructured":"Diamond I, Wrubel B, Estrin W, Gordon A. Basal and adenosine receptor-stimulated levels of cAMP are reduced in lymphocytes from alcoholic patients. Proc Natl Acad Sci. 1987;84:1413\u20136.","journal-title":"Proc Natl Acad Sci"},{"key":"3267_CR59","doi-asserted-by":"publisher","first-page":"G681","DOI":"10.1152\/ajpgi.00098.2006","volume":"291","author":"L Gobejishvili","year":"2006","unstructured":"Gobejishvili L, Barve S, Joshi-Barve S, Uriarte S, Song Z, McClain C. Chronic ethanol-mediated decrease in cAMP primes macrophages to enhanced LPS-inducible NF-\u03baB activity and TNF expression: relevance to alcoholic liver disease. Am J Physiol-Gastrointest Liver Physiol. 2006;291:G681\u2013G8.","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"3267_CR60","doi-asserted-by":"publisher","first-page":"G718","DOI":"10.1152\/ajpgi.90232.2008","volume":"295","author":"L Gobejishvili","year":"2008","unstructured":"Gobejishvili L, Barve S, Joshi-Barve S, McClain C. Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol-Gastrointest Liver Physiol. 2008;295:G718\u2013G24.","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"3267_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ejphar.2011.12.045","volume":"679","author":"AR Aroor","year":"2012","unstructured":"Aroor AR, Jackson DE, Shukla SD. Dysregulated phosphorylation and nuclear translocation of cyclic AMP response element binding protein (CREB) in rat liver after chronic ethanol binge. Eur J Pharmacol. 2012;679:101\u20138.","journal-title":"Eur J Pharmacol"},{"key":"3267_CR62","doi-asserted-by":"crossref","unstructured":"Avila DV, Barker DF, Zhang J, McClain CJ, Barve S, Gobejishvili L. Dysregulation of hepatic cAMP levels via altered Pde4b expression plays a critical role in alcohol\u2010induced steatosis. J Pathol. 2016;240:96\u2013107.","DOI":"10.1002\/path.4760"},{"key":"3267_CR63","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/hep.30761","volume":"70","author":"WE Rodriguez","year":"2019","unstructured":"Rodriguez WE, Wahlang B, Wang Y, Zhang J, Vadhanam MV, Joshi\u2010Barve S, et al. Phosphodiesterase 4 inhibition as a therapeutic target for alcoholic liver disease: from bedside to bench. Hepatology. 2019;70:1958\u201371.","journal-title":"Hepatology"},{"key":"3267_CR64","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.3390\/pharmaceutics14091894","volume":"14","author":"J Ma","year":"2022","unstructured":"Ma J, Kumar V, Mahato RI. Nanoparticle delivery of novel PDE4B inhibitor for the treatment of alcoholic liver disease. Pharmaceutics. 2022;14:1894.","journal-title":"Pharmaceutics"},{"key":"3267_CR65","first-page":"a16","volume":"4","author":"C Yap","year":"1999","unstructured":"Yap C, Yuan Q, Ingelman-Sundberg M, French S. Role of CYP2E1 in the pathogenesis of alcoholic liver disease: modifications by cAMP and ubiquitin-proteasome pathway. Front Biosci. 1999;4:a16\u201325.","journal-title":"Front Biosci"},{"key":"3267_CR66","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1038\/sj.bjp.0702911","volume":"128","author":"CD Manning","year":"1999","unstructured":"Manning CD, Burman M, Christensen SB, Cieslinski LB, Essayan DM, Grous M, et al. Suppression of human inflammatory cell function by subtype\u2010selective PDE4 inhibitors correlates with inhibition of PDE4A and PDE4B. Br J Pharmacol. 1999;128:1393\u20138.","journal-title":"Br J Pharmacol"},{"key":"3267_CR67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","volume":"7","author":"C Zhang","year":"2017","unstructured":"Zhang C, Xu Y, Zhang H-T, Gurney ME, O\u2019Donnell JM. Comparison of the pharmacological profiles of selective PDE4B and PDE4D inhibitors in the central nervous system. Sci Rep. 2017;7:1\u201310.","journal-title":"Sci Rep"},{"key":"3267_CR68","doi-asserted-by":"crossref","unstructured":"Zheng L, Aimaiti Z, Long L, Xia C, Wang W, Zhou Z-Z. Discovery of 4-ethoxy-6-chloro-5-azaindazoles as novel PDE4 inhibitors for the treatment of alcohol use disorder and alcoholic liver diseases. J Med Chem. 2023;67:728\u201353.","DOI":"10.1021\/acs.jmedchem.3c02087"},{"key":"3267_CR69","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1007\/s00213-014-3852-3","volume":"232","author":"KM Franklin","year":"2015","unstructured":"Franklin KM, Hauser SR, Lasek AW, McClintick J, Ding Z-M, McBride WJ, et al. Reduction of alcohol drinking of alcohol-preferring (P) and high-alcohol drinking (HAD1) rats by targeting phosphodiesterase-4 (PDE4). Psychopharmacology. 2015;232:2251\u201362.","journal-title":"Psychopharmacology"},{"key":"3267_CR70","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1111\/j.1530-0277.2012.01845.x","volume":"36","author":"RT Wen","year":"2012","unstructured":"Wen RT, Zhang M, Qin WJ, Liu Q, Wang WP, Lawrence AJ, et al. The phosphodiesterase\u20104 (PDE 4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol\u2010preferring fawn\u2010hooded rats. Alcohol: Clin Exp Res. 2012;36:2157\u201367.","journal-title":"Alcohol: Clin Exp Res"},{"key":"3267_CR71","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s00213-011-2290-8","volume":"218","author":"W Hu","year":"2011","unstructured":"Hu W, Lu T, Chen A, Huang Y, Hansen R, Chandler LJ, et al. Inhibition of phosphodiesterase-4 decreases ethanol intake in mice. Psychopharmacology. 2011;218:331\u20139.","journal-title":"Psychopharmacology"},{"key":"3267_CR72","doi-asserted-by":"publisher","first-page":"89791","DOI":"10.3389\/fnins.2014.00129","volume":"8","author":"YA Blednov","year":"2014","unstructured":"Blednov YA, Benavidez JM, Black M, Harris RA. Inhibition of phosphodiesterase 4 reduces ethanol intake and preference in C57BL\/6J mice. Front Neurosci. 2014;8:89791.","journal-title":"Front Neurosci"},{"key":"3267_CR73","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/acer.13616","volume":"42","author":"YA Blednov","year":"2018","unstructured":"Blednov YA, Da Costa AJ, Tarbox T, Ponomareva O, Messing RO, Harris RA. Apremilast alters behavioral responses to ethanol in mice: I. Reduced consumption and preference. Alcohol Clin Exp Res. 2018;42:926\u201338.","journal-title":"Alcohol Clin Exp Res"},{"key":"3267_CR74","doi-asserted-by":"publisher","first-page":"2409","DOI":"10.1007\/s00213-017-4631-8","volume":"234","author":"X Liu","year":"2017","unstructured":"Liu X, Hao P-D, Yang M-F, Sun J-Y, Mao L-L, Fan C-D, et al. The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL\/6J mice. Psychopharmacology. 2017;234:2409\u201319.","journal-title":"Psychopharmacology"},{"key":"3267_CR75","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.3748\/wjg.v13.i34.4539","volume":"13","author":"M Duvnjak","year":"2007","unstructured":"Duvnjak M, Leroti\u0107 I, Bar\u0161i\u0107 N, Toma\u0161i\u0107 V, Juki\u0107 LV, Velagi\u0107 V. Pathogenesis and management issues for non-alcoholic fatty liver disease. World J Gastroenterol. 2007;13:4539.","journal-title":"World J Gastroenterol"},{"key":"3267_CR76","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1146\/annurev-pathol-012615-044224","volume":"11","author":"T Hardy","year":"2016","unstructured":"Hardy T, Oakley F, Anstee QM, Day CP. Nonalcoholic fatty liver disease: pathogenesis and disease spectrum. Annu Rev Pathol: Mech Dis. 2016;11:451\u201396.","journal-title":"Annu Rev Pathol: Mech Dis"},{"key":"3267_CR77","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/qjmed\/hcp158","volume":"103","author":"JK Dowman","year":"2010","unstructured":"Dowman JK, Tomlinson J, Newsome P. Pathogenesis of non-alcoholic fatty liver disease. QJM Int J Med. 2010;103:71\u201383.","journal-title":"QJM Int J Med"},{"key":"3267_CR78","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1146\/annurev-pathol-121808-102132","volume":"5","author":"DG Tiniakos","year":"2010","unstructured":"Tiniakos DG, Vos MB, Brunt EM. Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010;5:145\u201371.","journal-title":"Annu Rev Pathol"},{"key":"3267_CR79","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1111\/j.1467-789X.2009.00657.x","volume":"11","author":"G Musso","year":"2010","unstructured":"Musso G, Gambino R, Cassader M. Non\u2010alcoholic fatty liver disease from pathogenesis to management: an update. Obes Rev. 2010;11:430\u201345.","journal-title":"Obes Rev"},{"key":"3267_CR80","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","volume":"65","author":"E Buzzetti","year":"2016","unstructured":"Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism. 2016;65:1038\u201348.","journal-title":"Metabolism"},{"key":"3267_CR81","doi-asserted-by":"publisher","first-page":"G1135","DOI":"10.1152\/ajpgi.2001.281.5.G1135","volume":"281","author":"G Robertson","year":"2001","unstructured":"Robertson G, Leclercq I, Farrell GC. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol-Gastrointest Liver Physiol. 2001;281:G1135\u2013G9.","journal-title":"Am J Physiol-Gastrointest Liver Physiol"},{"key":"3267_CR82","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.freeradbiomed.2020.02.025","volume":"152","author":"Z Chen","year":"2020","unstructured":"Chen Z, Tian R, She Z, Cai J, Li H. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease. Free Radic Biol Med. 2020;152:116\u201341.","journal-title":"Free Radic Biol Med"},{"key":"3267_CR83","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/biom10121702","volume":"10","author":"C Rives","year":"2020","unstructured":"Rives C, Fougerat A, Ellero-Simatos S, Loiseau N, Guillou H, Gamet-Payrastre L, et al. Oxidative stress in NAFLD: role of nutrients and food contaminants. Biomolecules. 2020;10:1702.","journal-title":"Biomolecules"},{"key":"3267_CR84","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jhep.2018.06.008","volume":"69","author":"C Lebeaupin","year":"2018","unstructured":"Lebeaupin C, Vall\u00e9e D, Hazari Y, Hetz C, Chevet E, Bailly-Maitre B. Endoplasmic reticulum stress signalling and the pathogenesis of non-alcoholic fatty liver disease. J Hepatol. 2018;69:927\u201347.","journal-title":"J Hepatol"},{"key":"3267_CR85","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3748\/wjg.v20.i7.1768","volume":"20","author":"X-Q Zhang","year":"2014","unstructured":"Zhang X-Q, Xu C-F, Yu C-H, Chen W-X, Li Y-M. Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20:1768.","journal-title":"World J Gastroenterol"},{"key":"3267_CR86","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1038\/nrgastro.2013.149","volume":"10","author":"A Wree","year":"2013","unstructured":"Wree A, Broderick L, Canbay A, Hoffman HM, Feldstein AE. From NAFLD to NASH to cirrhosis\u2014new insights into disease mechanisms. Nat Rev Gastroenterol Hepatol. 2013;10:627\u201336.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3267_CR87","doi-asserted-by":"publisher","first-page":"101882","DOI":"10.1016\/j.molmet.2024.101882","volume":"80","author":"J Wang","year":"2024","unstructured":"Wang J, Guo Y, He Y, Qin Y, Li X, Yang L, et al. Hepatic regulator of G protein signaling 14 ameliorates NAFLD through activating cAMP-AMPK signaling by targeting Gi\u03b11\/3. Mol Metab. 2024;80:101882.","journal-title":"Mol Metab"},{"key":"3267_CR88","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44242-7","volume":"14","author":"M Chen","year":"2023","unstructured":"Chen M, Zhu J-Y, Mu W-J, Luo H-Y, Li Y, Li S, et al. Cdo1-Camkk2-AMPK axis confers the protective effects of exercise against NAFLD in mice. Nat Commun. 2023;14:8391.","journal-title":"Nat Commun"},{"key":"3267_CR89","doi-asserted-by":"publisher","first-page":"889858","DOI":"10.3389\/fendo.2022.889858","volume":"13","author":"S Xu","year":"2022","unstructured":"Xu S, Wang Y, Li Z, Fan X. LncRNA GAS5 knockdown mitigates hepatic lipid accumulation via regulating MiR-26a-5p\/PDE4B to activate cAMP\/CREB pathway. Front Endocrinol. 2022;13:889858.","journal-title":"Front Endocrinol"},{"key":"3267_CR90","doi-asserted-by":"publisher","first-page":"106004","DOI":"10.1016\/j.phrs.2021.106004","volume":"175","author":"X Tao","year":"2022","unstructured":"Tao X, He H, Peng J, Xu R, Fu J, Hu Y, et al. Overexpression of PDE4D in mouse liver is sufficient to trigger NAFLD and hypertension in a CD36-TGF-\u03b21 pathway: therapeutic role of roflumilast. Pharmacol Res. 2022;175:106004.","journal-title":"Pharmacol Res"},{"key":"3267_CR91","doi-asserted-by":"crossref","unstructured":"Yu Y, He C, Tan S, Huang M, Guo Y, Li M et al. MicroRNA-137-3p improves nonalcoholic fatty liver disease through activating AMPK\u03b1. Anal Cell Pathol. 2021;2021:4853355.","DOI":"10.1155\/2021\/4853355"},{"key":"3267_CR92","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1111\/fcp.12530","volume":"34","author":"RM El\u2010Deen","year":"2020","unstructured":"El\u2010Deen RM, Heeba GH, Abdel\u2010latif RG, Khalifa MM. Comparative effectiveness of phosphodiesterase 3, 4, and 5 inhibitors in amelioration of high\u2010fat diet\u2010induced nonalcoholic fatty liver in rats. Fundam Clin Pharmacol. 2020;34:353\u201364.","journal-title":"Fundam Clin Pharmacol"},{"key":"3267_CR93","doi-asserted-by":"publisher","first-page":"e125","DOI":"10.1111\/1346-8138.16286","volume":"49","author":"K Ikumi","year":"2022","unstructured":"Ikumi K, Torii K, Sagawa Y, Kanayama Y, Nakada A, Nishihara H, et al. Phosphodiesterase 4 inhibitor apremilast improves insulin resistance in psoriasis patients. J Dermatol. 2022;49:e125.","journal-title":"J Dermatol"},{"key":"3267_CR94","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/dom.12839","volume":"19","author":"J M\u00f6llmann","year":"2017","unstructured":"M\u00f6llmann J, Kahles F, Lebherz C, Kappel B, Baeck C, Tacke F, et al. The PDE4 inhibitor roflumilast reduces weight gain by increasing energy expenditure and leads to improved glucose metabolism. Diab Obes Metab. 2017;19:496\u2013508.","journal-title":"Diab Obes Metab"},{"key":"3267_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-230X-8-40","volume":"8","author":"L Bujanda","year":"2008","unstructured":"Bujanda L, Hijona E, Larzabal M, Beraza M, Aldazabal P, Garc\u00eda-Urkia N, et al. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol. 2008;8:1\u20138.","journal-title":"BMC Gastroenterol"},{"key":"3267_CR96","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1017\/S0007114511002753","volume":"107","author":"S G\u00f3mez-Zorita","year":"2012","unstructured":"G\u00f3mez-Zorita S, Fern\u00e1ndez-Quintela A, Macarulla M, Aguirre L, Hijona E, Bujanda L, et al. Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br J Nutr. 2012;107:202\u201310.","journal-title":"Br J Nutr"},{"key":"3267_CR97","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.fct.2013.08.036","volume":"63","author":"L Li","year":"2014","unstructured":"Li L, Hai J, Li Z, Zhang Y, Peng H, Li K, et al. Resveratrol modulates autophagy and NF-\u03baB activity in a murine model for treating non-alcoholic fatty liver disease. Food Chem Toxicol. 2014;63:166\u201373.","journal-title":"Food Chem Toxicol"},{"key":"3267_CR98","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.nutres.2012.08.004","volume":"32","author":"MM Poulsen","year":"2012","unstructured":"Poulsen MM, Larsen J\u00d8, Hamilton-Dutoit S, Clasen BF, Jessen N, Paulsen SK, et al. Resveratrol up-regulates hepatic uncoupling protein 2 and prevents development of nonalcoholic fatty liver disease in rats fed a high-fat diet. Nutr Res. 2012;32:701\u20138.","journal-title":"Nutr Res"},{"key":"3267_CR99","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.dld.2014.11.015","volume":"47","author":"S Chen","year":"2015","unstructured":"Chen S, Zhao X, Ran L, Wan J, Wang X, Qin Y, et al. Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig Liver Dis. 2015;47:226\u201332.","journal-title":"Dig Liver Dis"},{"key":"3267_CR100","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/j.nutres.2014.09.005","volume":"34","author":"F Faghihzadeh","year":"2014","unstructured":"Faghihzadeh F, Adibi P, Rafiei R, Hekmatdoost A. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease. Nutr Res. 2014;34:837\u201343.","journal-title":"Nutr Res"},{"key":"3267_CR101","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3109\/00365521.2015.1107620","volume":"51","author":"S Heeb\u00f8ll","year":"2016","unstructured":"Heeb\u00f8ll S, Kreuzfeldt M, Hamilton-Dutoit S, Kj\u00e6r Poulsen M, St\u00f8dkilde-J\u00f8rgensen H, M\u00f8ller HJ, et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand J Gastroenterol. 2016;51:456\u201364.","journal-title":"Scand J Gastroenterol"},{"key":"3267_CR102","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.cgh.2014.02.024","volume":"12","author":"VS Chachay","year":"2014","unstructured":"Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O\u2019Moore\u2013Sullivan TM, Lee P, et al. Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014;12:2092\u2013103.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3267_CR103","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1080\/07315724.2017.1392264","volume":"37","author":"S Asghari","year":"2018","unstructured":"Asghari S, Asghari-Jafarabadi M, Somi M-H, Ghavami S-M, Rafraf M. Comparison of calorie-restricted diet and resveratrol supplementation on anthropometric indices, metabolic parameters, and serum sirtuin-1 levels in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial. J Am Coll Nutr. 2018;37:223\u201333.","journal-title":"J Am Coll Nutr"},{"key":"3267_CR104","doi-asserted-by":"publisher","first-page":"307","DOI":"10.15171\/apb.2018.036","volume":"8","author":"S Asghari","year":"2018","unstructured":"Asghari S, Rafraf M, Farzin L, Asghari-Jafarabadi M, Ghavami S-M, Somi M-H. Effects of pharmacologic dose of resveratrol supplementation on oxidative\/antioxidative status biomarkers in nonalcoholic fatty liver disease patients: a randomized, double-blind, placebo-controlled trial. Adv Pharm Bull. 2018;8:307.","journal-title":"Adv Pharm Bull"},{"key":"3267_CR105","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1017\/S0007114515002433","volume":"114","author":"F Faghihzadeh","year":"2015","unstructured":"Faghihzadeh F, Adibi P, Hekmatdoost A. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2015;114:796\u2013803.","journal-title":"Br J Nutr"},{"key":"3267_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12872-022-02637-2","volume":"22","author":"A Ali Sangouni","year":"2022","unstructured":"Ali Sangouni A, Abdollahi S, Mozaffari-Khosravi H. Effect of resveratrol supplementation on hepatic steatosis and cardiovascular indices in overweight subjects with type 2 diabetes: a double-blind, randomized controlled trial. BMC Cardiovasc Disord. 2022;22:212.","journal-title":"BMC Cardiovasc Disord"},{"key":"3267_CR107","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1111\/dom.13268","volume":"20","author":"K Kantartzis","year":"2018","unstructured":"Kantartzis K, Fritsche L, Bombrich M, Machann J, Schick F, Staiger H, et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin\u2010resistant subjects: A randomized, double\u2010blind, placebo\u2010controlled clinical trial. Diabetes Obes Metab. 2018;20:1793\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"3267_CR108","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1002\/hep.24544","volume":"54","author":"CO Zein","year":"2011","unstructured":"Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo\u2010controlled trial. Hepatology. 2011;54:1610\u20139.","journal-title":"Hepatology"},{"key":"3267_CR109","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1016\/j.cgh.2014.01.040","volume":"12","author":"V Ratziu","year":"2014","unstructured":"Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, et al. Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014;12:1724\u201330.e5.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3267_CR110","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42162-0","volume":"14","author":"Y Hu","year":"2023","unstructured":"Hu Y, Li H, Zhang H, Chen X, Chen J, Xu Z, et al. ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib\/IIa trial. Nat Commun. 2023;14:6409.","journal-title":"Nat Commun"},{"key":"3267_CR111","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI24282","volume":"115","author":"R Bataller","year":"2005","unstructured":"Bataller R, Brenner DA. Liver fibrosis. J Clin Investig. 2005;115:209\u201318.","journal-title":"J Clin Investig"},{"key":"3267_CR112","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1002\/cphy.c120026","volume":"3","author":"LJ Dixon","year":"2013","unstructured":"Dixon LJ, Barnes M, Tang H, Pritchard MT, Nagy LE. Kupffer cells in the liver. Compr Physiol. 2013;3:785.","journal-title":"Compr Physiol"},{"key":"3267_CR113","doi-asserted-by":"publisher","first-page":"7413","DOI":"10.3748\/wjg.v12.i46.7413","volume":"12","author":"G Kolios","year":"2006","unstructured":"Kolios G, Valatas V, Kouroumalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol. 2006;12:7413.","journal-title":"World J Gastroenterol"},{"key":"3267_CR114","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18:151\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3267_CR115","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1002\/cphy.c120035","volume":"3","author":"JE Puche","year":"2013","unstructured":"Puche JE, Saiman Y, Friedman SL. Hepatic stellate cells and liver fibrosis. Compr Physiol. 2013;3:1473\u201392.","journal-title":"Compr Physiol"},{"key":"3267_CR116","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1038\/nrgastro.2017.38","volume":"14","author":"T Tsuchida","year":"2017","unstructured":"Tsuchida T, Friedman SL. Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol. 2017;14:397\u2013411.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"3267_CR117","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1172\/JCI119291","volume":"99","author":"K Houglum","year":"1997","unstructured":"Houglum K, Lee KS, Chojkier M. Proliferation of hepatic stellate cells is inhibited by phosphorylation of CREB on serine 133. J Clin Investig. 1997;99:1322\u20138.","journal-title":"J Clin Investig"},{"key":"3267_CR118","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1007\/BF02091547","volume":"41","author":"N Kawada","year":"1996","unstructured":"Kawada N, Kuroki T, Kobayashi K, Inoue M, Kaneda K. Inhibition of myofibroblastic transformation of cultured rat hepatic stellate cells by methylxanthines and dibutyryl cAMP. Dig Dis Sci. 1996;41:1022\u20139.","journal-title":"Dig Dis Sci"},{"key":"3267_CR119","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1074\/jbc.M109.038620","volume":"285","author":"M Schiller","year":"2010","unstructured":"Schiller M, Dennler S, Anderegg U, Kokot A, Simon JC, Luger TA, et al. Increased cAMP levels modulate transforming growth factor-\u03b2\/smad-induced expression of extracellular matrix components and other key fibroblast effector functions. J Biol Chem. 2010;285:409\u201321.","journal-title":"J Biol Chem"},{"key":"3267_CR120","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1124\/mol.106.028951","volume":"70","author":"X Liu","year":"2006","unstructured":"Liu X, Sun SQ, Hassid A, Ostrom RS. cAMP inhibits transforming growth factor-\u03b2-stimulated collagen synthesis via inhibition of extracellular signal-regulated kinase 1\/2 and Smad signaling in cardiac fibroblasts. Mol Pharmacol. 2006;70:1992\u20132003.","journal-title":"Mol Pharmacol"},{"key":"3267_CR121","doi-asserted-by":"publisher","first-page":"8881","DOI":"10.1038\/sj.onc.1206871","volume":"22","author":"M Schiller","year":"2003","unstructured":"Schiller M, Verrecchia F, Mauviel A. Cyclic adenosine 3\u2032, 5\u2032-monophosphate-elevating agents inhibit transforming growth factor-\u03b2-induced SMAD3\/4-dependent transcription via a protein kinase A-dependent mechanism. Oncogene. 2003;22:8881\u201390.","journal-title":"Oncogene"},{"key":"3267_CR122","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1139\/cjpp-2015-0437","volume":"94","author":"Y Yang","year":"2016","unstructured":"Yang Y, Yang F, Wu X, Lv X, Li J. EPAC activation inhibits acetaldehyde-induced activation and proliferation of hepatic stellate cell via Rap1. Can J Physiol Pharmacol. 2016;94:498\u2013507.","journal-title":"Can J Physiol Pharmacol"},{"key":"3267_CR123","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1124\/jpet.117.241646","volume":"363","author":"M Schippers","year":"2017","unstructured":"Schippers M, Beljaars L, Post E, Lotersztajn S, Reker-Smit C, Han B, et al. Upregulation of Epac-1 in hepatic stellate cells by prostaglandin E2 in liver fibrosis is associated with reduced fibrogenesis. J Pharmacol Exp Ther. 2017;363:126\u201335.","journal-title":"J Pharmacol Exp Ther"},{"key":"3267_CR124","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/path.6194","volume":"261","author":"M Elnagdy","year":"2023","unstructured":"Elnagdy M, Wang Y, Rodriguez W, Zhang J, Bauer P, Wilkey DW, et al. Increased expression of phosphodiesterase 4 in activated hepatic stellate cells promotes cytoskeleton remodeling and cell migration. J Pathol. 2023;261:361\u201371.","journal-title":"J Pathol"},{"key":"3267_CR125","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1124\/jpet.113.204933","volume":"347","author":"L Gobejishvili","year":"2013","unstructured":"Gobejishvili L, Barve S, Breitkopf-Heinlein K, Li Y, Zhang J, Avila DV, et al. Rolipram attenuates bile duct ligation\u2013induced liver injury in rats: a potential pathogenic role of PDE4. J Pharmacol Exp Ther. 2013;347:80\u201390.","journal-title":"J Pharmacol Exp Ther"},{"key":"3267_CR126","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1111\/bph.13611","volume":"173","author":"NN El\u2010Agroudy","year":"2016","unstructured":"El\u2010Agroudy NN, El\u2010Naga RN, El\u2010Razeq RA, El\u2010Demerdash E. Forskolin, a hedgehog signalling inhibitor, attenuates carbon tetrachloride\u2010induced liver fibrosis in rats. Br J Pharmacol. 2016;173:3248\u201360.","journal-title":"Br J Pharmacol"},{"key":"3267_CR127","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.lfs.2019.03.014","volume":"222","author":"RM Essam","year":"2019","unstructured":"Essam RM, Ahmed LA, Abdelsalam RM, El-Khatib AS. Phosphodiestrase-1 and 4 inhibitors ameliorate liver fibrosis in rats: modulation of cAMP\/CREB\/TLR4 inflammatory and fibrogenic pathways. Life Sci. 2019;222:245\u201354.","journal-title":"Life Sci"},{"key":"3267_CR128","doi-asserted-by":"publisher","first-page":"e0216301","DOI":"10.1371\/journal.pone.0216301","volume":"14","author":"SA El Awdan","year":"2019","unstructured":"El Awdan SA, Abdel Rahman RF, Ibrahim HM, Hegazy RR, El Marasy SA, Badawi M, et al. Regression of fibrosis by cilostazol in a rat model of thioacetamide-induced liver fibrosis: up regulation of hepatic cAMP, and modulation of inflammatory, oxidative stress and apoptotic biomarkers. PloS One. 2019;14:e0216301.","journal-title":"PloS One"},{"key":"3267_CR129","doi-asserted-by":"publisher","first-page":"115194","DOI":"10.1016\/j.ejmech.2023.115194","volume":"250","author":"J-X Huang","year":"2023","unstructured":"Huang J-X, Zhu B-L, Xu J-P, Zhou Z-Z. Advances in the development of phosphodiesterase 7 inhibitors. Eur J Med Chem. 2023;250:115194.","journal-title":"Eur J Med Chem"},{"key":"3267_CR130","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1016\/S0960-894X(00)80054-2","volume":"3","author":"I Pinto","year":"1993","unstructured":"Pinto I, Buckle D, Readshaw S, Smith D. The selective inhibition of phosphodiesterase IV by benzopyran derivatives of rolipram. Bioorg Med Chem Lett. 1993;3:1743\u20136.","journal-title":"Bioorg Med Chem Lett"},{"key":"3267_CR131","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/S0960-894X(01)80384-X","volume":"4","author":"JA Stafford","year":"1994","unstructured":"Stafford JA, Feldman PL, Marron BE, Schoenen FJ, Valvano NL, Unwalla RJ, et al. Structure-activity relationships involving the catechol subunit of rolipram. Bioorg Med Chem Lett. 1994;4:1855\u201360.","journal-title":"Bioorg Med Chem Lett"},{"key":"3267_CR132","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ejmech.2016.08.052","volume":"124","author":"Z-Z Zhou","year":"2016","unstructured":"Zhou Z-Z, Ge B-C, Zhong Q-P, Huang C, Cheng Y-F, Yang X-M, et al. Development of highly potent phosphodiesterase 4 inhibitors with anti-neuroinflammation potential: design, synthesis, and structure-activity relationship study of catecholamides bearing aromatic rings. Eur J Med Chem. 2016;124:372\u20139.","journal-title":"Eur J Med Chem"},{"key":"3267_CR133","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1021\/jm900210d","volume":"52","author":"H-W Man","year":"2009","unstructured":"Man H-W, Schafer P, Wong LM, Patterson RT, Corral LG, Raymon H. et al. Discovery of (S)-N-{2-[1-(3-ethoxy-4-methoxyphenyl)-2-methanesulfonylethyl]-1, 3-dioxo-2, 3-dihydro-1 H-isoindol-4-yl} acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-\u03b1 inhibitor. J Med Chem. 2009;52:1522\u20134.","journal-title":"J Med Chem"},{"key":"3267_CR134","doi-asserted-by":"publisher","first-page":"113171","DOI":"10.1016\/j.ejmech.2021.113171","volume":"213","author":"Z Chu","year":"2021","unstructured":"Chu Z, Xu Q, Zhu Q, Ma X, Mo J, Lin G, et al. Design, synthesis and biological evaluation of novel benzoxaborole derivatives as potent PDE4 inhibitors for topical treatment of atopic dermatitis. Eur J Med Chem. 2021;213:113171.","journal-title":"Eur J Med Chem"},{"key":"3267_CR135","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0021-5198(19)43290-3","volume":"46","author":"K Takagi","year":"1988","unstructured":"Takagi K, Hasegawa T, Kuzuya T, Ogawa K, Watanabe T, Satake T, et al. Structure-activity relationship in N3-alkyl-xanthine derivatives. Jpn J Pharmacol. 1988;46:373\u20138.","journal-title":"Jpn J Pharmacol"},{"key":"3267_CR136","doi-asserted-by":"publisher","first-page":"5451","DOI":"10.1016\/j.bmcl.2011.06.118","volume":"21","author":"K Ochiai","year":"2011","unstructured":"Ochiai K, Ando N, Iwase K, Kishi T, Fukuchi K, Ohinata A, et al. Phosphodiesterase inhibitors. Part 2: Design, synthesis, and structure\u2013activity relationships of dual PDE3\/4-inhibitory pyrazolo [1, 5-a] pyridines with anti-inflammatory and bronchodilatory activity. Bioorg Med Chem Lett. 2011;21:5451\u20136.","journal-title":"Bioorg Med Chem Lett"},{"key":"3267_CR137","doi-asserted-by":"publisher","first-page":"5311","DOI":"10.1016\/j.bmcl.2013.07.069","volume":"23","author":"A Kojima","year":"2013","unstructured":"Kojima A, Takita S, Sumiya T, Ochiai K, Iwase K, Kishi T, et al. Phosphodiesterase inhibitors. Part 6: Design, synthesis, and structure\u2013activity relationships of PDE4-inhibitory pyrazolo [1, 5-a] pyridines with anti-inflammatory activity. Bioorg Med Chem Lett. 2013;23:5311\u20136.","journal-title":"Bioorg Med Chem Lett"},{"key":"3267_CR138","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1016\/j.bmcl.2011.04.021","volume":"21","author":"RW Allcock","year":"2011","unstructured":"Allcock RW, Blakli H, Jiang Z, Johnston KA, Morgan KM, Rosair GM, et al. Phosphodiesterase inhibitors. Part 1: Synthesis and structure\u2013activity relationships of pyrazolopyridine\u2013pyridazinone PDE inhibitors developed from ibudilast. Bioorg Med Chem Lett. 2011;21:3307\u201312.","journal-title":"Bioorg Med Chem Lett"},{"key":"3267_CR139","doi-asserted-by":"crossref","unstructured":"Silvestre J, Graul A, Casta\u00f1er J. SB-207499. Antiasthmatic\/antiinflamatory, phosphodiesterase IV inhibitor. Drugs of the Future. 1998;23:607\u201315. Available from: https:\/\/access.portico.org\/stable?au=pjbf78x4mbm.","DOI":"10.1358\/dof.1998.023.06.457488"},{"key":"3267_CR140","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1021\/jm401549m","volume":"57","author":"E Armani","year":"2014","unstructured":"Armani E, Amari G, Rizzi A, Fanti RD, Ghidini E, Capaldi C, et al. Novel class of benzoic acid ester derivatives as potent PDE4 inhibitors for inhaled administration in the treatment of respiratory diseases. J Med Chem. 2014;57:793\u2013816.","journal-title":"J Med Chem"},{"key":"3267_CR141","doi-asserted-by":"crossref","unstructured":"Gurney ME, Nugent RA, Mo X, Sindac JA, Hagen TJ, Fox III D, et al. Design and synthesis of selective phosphodiesterase 4D (PDE4D) allosteric inhibitors for the treatment of fragile X syndrome and other brain disorders. J Med Chem. 2019;62:4884\u2013901.","DOI":"10.1021\/acs.jmedchem.9b00193"},{"key":"3267_CR142","doi-asserted-by":"publisher","first-page":"108567","DOI":"10.1016\/j.jmgm.2023.108567","volume":"124","author":"R Ma","year":"2023","unstructured":"Ma R, Song N, Wang L, Gu X, Xiong F, Zhang S, et al. Discovery of 2-(Methylcarbonylamino) thiazole as PDE4 inhibitors via virtual screening and biological evaluation. J Mol Graph Model. 2023;124:108567.","journal-title":"J Mol Graph Model"},{"key":"3267_CR143","doi-asserted-by":"publisher","first-page":"11518","DOI":"10.3390\/ijms241411518","volume":"24","author":"J Jin","year":"2023","unstructured":"Jin J, Mazzacuva F, Crocetti L, Giovannoni MP, Cilibrizzi A. PDE4 inhibitors: profiling hits through the multitude of structural classes. Int J Mol Sci. 2023;24:11518.","journal-title":"Int J Mol Sci"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-024-03267-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-024-03267-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-024-03267-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T19:10:03Z","timestamp":1723230603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-024-03267-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":143,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3267"],"URL":"https:\/\/doi.org\/10.1007\/s00044-024-03267-3","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]},"assertion":[{"value":"30 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}